Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGAIN phase 3 study of galcanezumab in chronic migraine
NL-OMON46093Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of galcanezumab in chronic migraine (3 arms), sponsored by Eli Lilly and Company. Started Feb 2016; status: active, not recruiting.
02
Drugs
galcanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NL-OMON46093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46093.